Literature DB >> 25524202

The Th1 chemokine IP-10 in Systemic sclerosis.

A Corrado1.   

Abstract

Many studies have suggested that IP-10/CXCR3 axis plays a critical role in the autoimmune process and in fibrosis in patients with systemic sclerosis (SSc). A longitudinal study demonstrated high serum levels of IP-10 [T-helper (Th)1] and MCP-1 (Th2) chemokines in newly diagnosed SSc. High values of IP-10 were associated with a more severe clinical phenotype (lung and kidney involvement). IP-10 declined during the follow-up, while MCP-1 remained unmodified, suggesting that the disease progresses from the early Th1 inflammatory condition to the advanced Th2-like stage. Other studies have shown that IP-10 is a marker of a more aggressive autoimmune process involving organs such as thyroid or lung. SSc fibroblasts show in vitro various types of dysregulated production of IP-10, when stimulated with cytokines, such as interferons (IFNs). Furthermore, it has been suggested that the IFN-inducible chemokine IP-10 is a stable serologic marker of a more severe form of SSc and may be useful for risk stratification of patients, regardless of disease type (limited or diffuse).

Entities:  

Keywords:  Chemokines; IP-10; SSc

Mesh:

Substances:

Year:  2014        PMID: 25524202     DOI: 10.7417/CT.2014.1789

Source DB:  PubMed          Journal:  Clin Ter        ISSN: 0009-9074


  3 in total

Review 1.  Certainties and uncertainties concerning the contribution of pericytes to the pathogenesis of systemic sclerosis.

Authors:  Rossella Talotta; Fabiola Atzeni; Maria Chiara Ditto; Maria Chiara Gerardi; Alberto Batticciotto; Sara Bongiovanni; Piercarlo Sarzi Puttini
Journal:  J Scleroderma Relat Disord       Date:  2017-09-09

2.  The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis.

Authors:  Tania Colasanti; Katia Stefanantoni; Cristina Fantini; Clarissa Corinaldesi; Massimiliano Vasile; Francesco Marampon; Luigi Di Luigi; Cristina Antinozzi; Paolo Sgrò; Andrea Lenzi; Valeria Riccieri; Clara Crescioli
Journal:  Int J Mol Sci       Date:  2022-09-05       Impact factor: 6.208

3.  Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment.

Authors:  Anton A A Smith; Emily C Gale; Gillie A Roth; Caitlin L Maikawa; Santiago Correa; Anthony C Yu; Eric A Appel
Journal:  Biomacromolecules       Date:  2020-08-20       Impact factor: 6.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.